marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Applied Therapeutics Financial Ratios 2011-2024 | APLT
Annual Financial Ratios Applied Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-4.5 | -0.4 | -0.7 | -5.0 | -15.0 | - | - | - | - | - | - | - | - |
P/S |
54.1 | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-1.4 | -2.2 | -4.1 | -4.3 | -3.5 | -3.0 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
563 M | 52.8 M | 52.3 M | 435 M | 679 M | -14.3 M | 7.25 M | - | - | - | - | - | - |
EBITDA per Share |
-0.77 | -2.19 | -4.13 | -4.2 | -3.55 | - | - | - | - | - | - | - | - |
EV/EBITDA |
-0.5 | -4.4 | -14.5 | - | - | - | - | - | - | - | - | ||
PEG |
- | 0.24 | 0.15 | - | - | - | - | - | - | - | - | ||
P/B |
-31.5 | 8.7 | 1.3 | 5.7 | 20.9 | - | - | - | - | - | - | - | - |
P/CF |
-9.8 | -0.5 | -0.9 | -6.0 | -18.8 | - | - | - | - | - | - | - | - |
ROE % |
698.49 | -2031.72 | -168.83 | -114.67 | -139.58 | - | - | - | - | - | - | - | - |
ROA % |
-218.41 | -215.07 | -117.46 | -89.91 | -94.06 | - | - | - | - | - | - | - | - |
ROCE % |
394.73 | -1679.49 | -166.51 | -113.44 | -132.93 | - | - | - | - | - | - | - | - |
Current Ratio |
0.8 | 1.1 | 3.3 | 4.8 | 3.3 | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Applied Therapeutics
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.48 | 0.02 | - | -0.47 | -0.37 | -0.18 | - | -0.4 | -0.96 | -0.88 | - | -1.09 | -0.99 | -1 | - | -1.33 | -1.27 | -0.59 | - | -0.63 | -0.6 | -1.58 | - | -0.78 | -0.58 | -0.43 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.21 | -0.14 | - | -0.17 | -0.22 | -0.19 | - | -0.4 | -0.8 | -0.88 | - | -1.09 | -0.99 | -1 | - | -1.34 | -1.28 | -0.6 | - | -0.63 | -0.6 | -1.58 | - | -0.6 | -0.43 | -0.34 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-392.84 | 1453.74 | 1315.03 | 1116.66 | 534.65 | -247.98 | -353.66 | -386.43 | -220.84 | -143.62 | -73.63 | -110.05 | -113.70 | -124.97 | -85.76 | -118.62 | -115.05 | -106.68 | -198.31 | -176.46 | -121.75 | -79.62 | 50.03 | 50.03 | 28.17 | 11.92 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-249.60 | -253.00 | -195.30 | -229.00 | -168.95 | -134.26 | -102.37 | -126.34 | -116.61 | -102.40 | -58.31 | -86.86 | -91.45 | -99.44 | -67.24 | -89.38 | -82.96 | -73.55 | -133.63 | -154.78 | -153.78 | -152.08 | -48.41 | -48.41 | -27.26 | -11.53 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-119.02 | 757.31 | 969.63 | 779.21 | 438.49 | -127.76 | -325.80 | -358.21 | -200.21 | -141.67 | -72.94 | -108.92 | -112.49 | -123.67 | -84.92 | -116.26 | -111.62 | -102.26 | -81.40 | -64.44 | -16.13 | 20.40 | 38.43 | 38.43 | 21.46 | 9.53 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.1 | 2.3 | 0.8 | 0.8 | 0.9 | 0.9 | 1.1 | 1.2 | 1.5 | 2.8 | 3.3 | 3.7 | 5.6 | 7.4 | 4.6 | 4.6 | 4.6 | 4.6 | 3.1 | 3.1 | 3.1 | 3.1 | 4.6 | 4.6 | 4.6 | 4.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency